Gastric Cancer (GC) Clinical Trials

16 recruitingLast updated: June 17, 2026

There are 16 actively recruiting gastric cancer (gc) clinical trials across 7 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3. Top locations include Shanghai, China, Duarte, California, United States, Beijing, China. Updated daily from ClinicalTrials.gov.


Gastric Cancer (GC) Trials at a Glance

16 actively recruiting trials for gastric cancer (gc) are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Shanghai, Duarte, and Beijing. Lead sponsors running gastric cancer (gc) studies include City of Hope Medical Center, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, and Beijing Friendship Hospital.

Browse gastric cancer (gc) trials by phase

Treatments under study

About Gastric Cancer (GC) Clinical Trials

Looking for clinical trials for Gastric Cancer (GC)? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastric Cancer (GC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastric Cancer (GC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 1

THE-0504 in Patients With Solid Tumors

Triple-Negative Breast CancerGastric Cancer (GC)Small Cell Lung Cancer ( SCLC )+2 more
Thena Biotech S.r.l.30 enrolled1 locationNCT07646106
Recruiting
Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

SarcomaNon-small Cell Lung CancerNSCLC+12 more
Epkin146 enrolled10 locationsNCT06789172
Recruiting
Not Applicable

Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer

Gastric Cancer (GC)Double-tract ReconstructionTubular Gastric Anastomosis
Qilu Hospital of Shandong University52 enrolled1 locationNCT07635836
Recruiting
Phase 3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

Esophageal CancerGastric Cancer (GC)Gastroesophageal Junction
SOFIE200 enrolled14 locationsNCT07217704
Recruiting
Phase 1

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC)Hepatocellular Carcinoma (HCC)Gastric Cancer (GC)+1 more
Shenzhen Xinhe Biomedical48 enrolled2 locationsNCT07594964
Recruiting

Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)

Gastric Cancer (GC)Locally Advanced Gastric Cancer
Qun Zhao2,000 enrolled9 locationsNCT07401199
Recruiting

Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer

Gastric Cancer (GC)Siewert Type III Adenocarcinoma of Esophagogastric JunctionSiewert Type II Adenocarcinoma of Esophagogastric Junction
P. Herzen Moscow Oncology Research Institute400 enrolled1 locationNCT07441785
Recruiting
Phase 1

A Study of SH009 Injection in Patients With Advanced Solid Tumors.

Esophageal CancerBreast Cancer (Locally Advanced or Metastatic)Lung Cancer (NSCLC)+4 more
Nanjing Sanhome Pharmaceutical, Co., Ltd.150 enrolled1 locationNCT07390838
Recruiting
Phase 3

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Gastric Cancer (GC)Adjuvant ChemotherapyOxaliplatin+2 more
Ruijin Hospital387 enrolled5 locationsNCT07366528
Recruiting

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

Gastric Cancer (GC)HIPECPeritoneal Metastases From Gastric Cancer+1 more
Ukrainian Society of Clinical Oncology200 enrolled1 locationNCT07313579
Recruiting
Phase 2

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Gastroesophageal-junction CancerMetastatic Gastric CancerAdvanced Gastric Cancer+1 more
Beijing Friendship Hospital32 enrolled1 locationNCT07315854
Recruiting
Phase 2

SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure

Gastroesophageal Junction AdenocarcinomaGastric Cancer (GC)
Jingdong Zhang40 enrolled1 locationNCT07311408
Recruiting

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)CholangiocarcinomaHepatocellular Carcinoma (HCC)+3 more
City of Hope Medical Center1,000 enrolled1 locationNCT07224750
Recruiting
Not Applicable

PPG vs. ICG in Gastrointestinal Resections

Colorectal, CancerGastric Cancer (GC)Postoperative Complications+3 more
Saint Petersburg State University, Russia200 enrolled3 locationsNCT06222645
Recruiting

The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer

Gastric Cancer (GC)No.4sb
Tianjin Medical University Cancer Institute and Hospital400 enrolled1 locationNCT07183150
Recruiting
Phase 2

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Neoadjuvant TherapyRadiotherapyImmunotherapy+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University40 enrolled1 locationNCT07165847